Verseon Corporation BIO-Europe Spring: Verseon presents anticoagulants
March 20 2017 - 2:01AM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
20 March 2017
Press release March 20, 2017
Verseon Corporation
("Verseon" or the "Company")
Verseon to showcase low bleeding risk anticoagulation candidates
at BIO-Europe Spring
FREMONT, Calif.-Tomorrow, Dr. David Kita, Vice President of
R&D at Verseon, will present preclinical results on the
Company's novel class of potent, highly selective direct thrombin
inhibitors at the 2017 BIO-Europe Spring conference in
Barcelona.
Verseon has developed multiple, chemically diverse drug
candidates that show efficacy comparable to the NOACs in
preclinical models of arterial and venous thromboembolism, but do
not disrupt platelet function. This distinguishing feature provides
a biological explanation for the reduced bleeding risk of the
Verseon inhibitors observed in preclinical testing.
The presentation will also cover Verseon's first development
candidate for clinical trials. The candidate has pharmacokinetics
suitable for oral dosing and is well tolerated even at high doses
in single and repeat dosing studies. Furthermore, this development
candidate exhibits very low renal clearance in preclinical studies,
a highly desirable property for patients with impaired kidney
function.
"Our drug candidates effectively inhibit thrombosis while
preserving hemostasis, striking a balance that is lacking in
current anticoagulants. This leads to the remarkably safe bleeding
profile of our candidates that will make them best-in-class
therapeutics," said Dr. Kita.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has three active drug programs in the areas
of anticoagulation, diabetic macular edema, and oncology.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Arthur Shmurun / Amy Thai 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKDNFDNXEFF
(END) Dow Jones Newswires
March 20, 2017 03:01 ET (07:01 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024